VRX
Valeant Pharmaceuticals International, Inc.
Set alert
Day range unavailable
- YTD
- -100.00%
- 1 year
- -100.00%
- Open
- —
- Prev close
- 24.11
- Mkt cap
- 8.17B
- Vol
- 0
- Avg vol
- 6.43M
- EPS
- 6.83
- P/E
- 3.43
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 6.67
- Beta
- -0.93
- Short ratio
- 1.80
- Inst. own
- 51.10%
- Dividend
- 0.00
- Ex-div date
- Nov 9, 2010
- 50-d avg
- 23.03
- 200-d avg
- 19.85
- 1y target
- 23.25
Key statistics
- Market cap
- 8.17B
- Enterprise value
- 32.38B
- Trailing P/E
- 3.43
- Forward P/E
- 6.67
- PEG ratio
- 3.05
- Price / sales
- 0.95
- Price / book
- 1.40
- EPS (TTM)
- 6.83
- Beta
- -0.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -10.65%
- Revenue (TTM)
- 8.61B
- Revenue growth
- -5.40%
- Free cash flow
- 2.52B
- Total cash
- 909.00M
- Total debt
- 25.27B
- Return on equity
- -21.51%
- Shares outstanding
- 349.30M
- Short % of float
- 4.72%
- 50-day average
- 23.03
- 200-day average
- 19.85
Analyst view
Consensus: hold
- Target (low)
- 9.00
- Target (mean)
- 23.25
- Target (high)
- 35.00
- Strong buy2
- Buy2
- Hold12
- Sell4
- Strong sell1
Next earnings
Consensus EPS estimate 0.78.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2018 | TD Securities | down | Buy | Hold |
| Jun 5, 2018 | Barclays | up | Equal-Weight | Overweight |
| May 14, 2018 | Mizuho | up | Neutral | Buy |
| Apr 5, 2018 | Mizuho | up | Underperform | Neutral |
| Jan 23, 2018 | Goldman Sachs | init | — | Sell |
| Dec 13, 2017 | JP Morgan | down | Neutral | Underweight |
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- valeant.com
News
- TD Ameritrade Traders Adopt Some Old And New Approaches To The Trade War Market In June's IMX
- 56 Biggest Movers From Yesterday
- 48 Stocks Moving In Tuesday's Mid-Day Session
- 40 Stocks Moving In Tuesday's Pre-Market Session
- Valeant, Financials And More: Fast Money Picks For June 29
- Mr. Wonderful's Election Week Trades For A Trump Victory
- Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
- Mid-Afternoon Market Update: Navistar Climbs Following Earnings Beat; Biogen Shares Tumble
- Mid-Day Market Update: LDR Rises On Acquisition News; DryShips Shares Drop
- Mid-Morning Market Update: Markets Mostly Higher; Valeant Earnings Miss Views
Your note
Sign in to keep a note on VRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DE SCHUTTER RICHARD U | Director | Stock Award(Grant) | May 2, 2018 | 118,787 |
| HALE DAVID ROBERT | Director | Stock Award(Grant) | May 2, 2018 | 0 |
| HERENDEEN PAUL S | Chief Financial Officer | Stock Award(Grant) | Mar 6, 2018 | 216,492 |
| KARABELAS ARGERIS N | Director | Stock Award(Grant) | May 2, 2018 | 60,417 |
| KAVANAGH, SARAH BALDWIN | Director | Stock Award(Grant) | May 2, 2018 | 54,149 |
| PAULSON JOHN A. | Director | Stock Award(Grant) | May 2, 2018 | 37,361 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paulson & Company, Inc. | 5.98% | 20,839,035 | 440.95M | Dec 30, 2017 |
| ValueAct Holdings, L.P. | 5.16% | 18,010,027 | 381.09M | Dec 30, 2017 |
| Renaissance Technologies, LLC | 3.05% | 10,651,189 | 225.38M | Dec 30, 2017 |
| Vanguard Group, Inc. (The) | 2.30% | 8,007,068 | 169.43M | Dec 30, 2017 |
| Miller Value Partners, LLC | 1.94% | 6,748,159 | 142.79M | Dec 30, 2017 |
| Toronto Dominion Bank | 1.74% | 6,067,701 | 128.39M | Dec 30, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust for Advised Port-Miller Opportunity Trust | 1.32% | 4,600,000 | 97.34M | Dec 30, 2017 |
| Vanguard International Stock Index-Total Intl Stock Indx | 1.21% | 4,220,536 | 71.07M | Jul 30, 2017 |
| Oppenheimer Main Street Fund | 0.57% | 1,983,050 | 28.22M | Aug 30, 2017 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 0.47% | 1,629,657 | 27.13M | Jun 29, 2017 |
| Legg Mason Clearbridge Aggressive Growth Fd | 0.43% | 1,507,645 | 31.90M | Dec 30, 2017 |
| DFA International Core Equity Portfolio | 0.30% | 1,033,457 | 17.40M | Jul 30, 2017 |